esmo advanced course on clinical questions in prostate ... · esmo advanced course programme...
TRANSCRIPT
esmo.org
Programme
ESMO Advanced Course on Clinical Questions in Prostate Cancer
SINGAPORE 6-7 SEPTEMBER 2019
Co-ChairsKarim Fizazi, FRRavindran Kanesvaran, SG
ESMO ADVANCED COURSE PROGRAMME
CLINICAL QUESTIONS IN PROSTATE CANCER
Singapore
6-7 September 2019
CO-CHAIRS: Karim Fizazi, France SPEAKERS: Arun Azad, Australia Ravindran Kanesvaran, Singapore Melvin L. K. Chua, Singapore
Jin Wei Kwek, Singapore
David Olmos Hidalgo, Spain
Darren M. C. Poon, Hong Kong
LEARNING OBJECTIVES
• To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
• To learn about state-of-the-art advances in treatment of prostate cancer
• To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios
ACCREDITATION
The programme of this event has been accredited with 8 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees
that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary
skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.
ACKNOWLEDGEMENTS
This event is supported by an unrestricted educational grant from
ORGANISATION AND CONTACTS
ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: [email protected]
www.esmo.org
Friday, , , , 6666 September September September September 2012012012019999
09:0009:0009:0009:00----09:2009:2009:2009:20 Welcome and course overviewWelcome and course overviewWelcome and course overviewWelcome and course overview
20ʼ Karim Fizazi, FR
Ravindran Kanesvaran, SG
09:209:209:209:20000----10:10:10:10:35353535 Session 1Session 1Session 1Session 1
StateStateStateState----ofofofof----thethethethe----art in prostate cancer diagnosticsart in prostate cancer diagnosticsart in prostate cancer diagnosticsart in prostate cancer diagnostics
20ʼ Updates in imaging
Jin Wei Kwek, SG
20ʼ PSA screening
Ravindran Kanesvaran, SG
20ʼ Biology: How cancer genetics can impact on clinical decision making?
David Olmos Hidalgo, ES
15ʼ Discussion
Faculty
10:35-11:00 Coffee break
11:11:11:11:00000000----12:12:12:12:00005555 Session 2Session 2Session 2Session 2
High risk lHigh risk lHigh risk lHigh risk localized prostate cancerocalized prostate cancerocalized prostate cancerocalized prostate cancer
25ʼ Role of radiotherapy: Recent advances in RT modalities
Melvin L. K. Chua, SG
25ʼ High risk localized disease: Integrating drugs with local treatments
Darren M. C. Poon, HK
15ʼ Discussion
Faculty
12:05-13:00 Lunch
13:13:13:13:00000000----11114:154:154:154:15 Session 3Session 3Session 3Session 3
Intermediate situation of advanced prostate cancerIntermediate situation of advanced prostate cancerIntermediate situation of advanced prostate cancerIntermediate situation of advanced prostate cancer
20ʼ Rising PSA: What to do?
Darren M. C. Poon, HK
20ʼ Oligometastatic prostate cancer
Melvin L. K. Chua, SG
20ʼ M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options?
Arun Azad, AU
15ʼ Discussion
Faculty
14:1514:1514:1514:15----11115555:5:5:5:50000 Session 4Session 4Session 4Session 4
Metastatic prostate cancer Metastatic prostate cancer Metastatic prostate cancer Metastatic prostate cancer
20ʼ Metastatic hormone sensitive prostate cancer: State-of-the-art management in 2019
Ravindran Kanesvaran, SG
20ʼ Metastatic CRPC: Standard of care in 2019
Arun Azad, AU
Session 4Session 4Session 4Session 4 ---- cont.cont.cont.cont.
Metastatic prostate cancer Metastatic prostate cancer Metastatic prostate cancer Metastatic prostate cancer
20ʼ Metastatic CRPC: What’s on the horizon - new treatments (PARP inhibitors, immunotherapy)?
Karim Fizazi, FR
15ʼ ESMO Magnitude of Clinical Benefit Scale
Ravindran Kanesvaran, SG
20ʼ Discussion and summary
Karim Fizazi, FR
Ravindran Kanesvaran, SG
15:50-16:20 Coffee break
16:16:16:16:20202020----17171717::::00000000 Tour of NCCS premisesTour of NCCS premisesTour of NCCS premisesTour of NCCS premises
19:00 Networking dinner
Saturday, , , , 7777 September 201September 201September 201September 2019999
09:0009:0009:0009:00----12:3012:3012:3012:30 WorkshopWorkshopWorkshopWorkshop sessionssessionssessionssessions
Three parallel workshop sessions with around 20 delegates in each group (delegates will attend all 3
sessions on a rotation basis)
15ʼ Introduction based on clinical cases presented by speakers
40ʼ Discussion
5ʼ Break
Workshop 1Workshop 1Workshop 1Workshop 1 Localized prostate cancerLocalized prostate cancerLocalized prostate cancerLocalized prostate cancer
60ʼ Melvin L. K. Chua, SG
Darren M. C. Poon, HK
Workshop 2Workshop 2Workshop 2Workshop 2 Intermediate advanced prostate cancerIntermediate advanced prostate cancerIntermediate advanced prostate cancerIntermediate advanced prostate cancer
60ʼ Arun Azad, AU
Ravindran Kanesvaran, SG
Workshop 3Workshop 3Workshop 3Workshop 3 Metastatic prostate cancerMetastatic prostate cancerMetastatic prostate cancerMetastatic prostate cancer
60ʼ Karim Fizazi, FR
David Olmos Hidalgo, ES
11:00-11:30 Coffee break
11:3011:3011:3011:30----11112222::::33330000 Workshops 1Workshops 1Workshops 1Workshops 1----2222----3 continuation3 continuation3 continuation3 continuation
12:3012:3012:3012:30----13:0013:0013:0013:00 Feedback on the workshopFeedback on the workshopFeedback on the workshopFeedback on the workshopssss from each groupfrom each groupfrom each groupfrom each group
13:0013:0013:0013:00----13:1513:1513:1513:15 Synthesis and wrapSynthesis and wrapSynthesis and wrapSynthesis and wrap----upupupup
15ʼ Karim Fizazi, FR
Ravindran Kanesvaran, SG
13:15-14:15 Lunch